Clinical Report: Deprescribing Seen in T2D Care
Overview
A retrospective chart review of 650 patients with type 2 diabetes revealed that deprescribing glucose-lowering medications was associated with significant reductions in body mass index, glucose levels, and hemoglobin A1c, with no serious adverse events reported. The findings suggest that deprescribing can be safely integrated into routine diabetes care.
Background
The management of type 2 diabetes often involves complex medication regimens that can lead to treatment burden and potential adverse effects. Deprescribing, or the systematic reduction of medications, is gaining attention as a strategy to optimize treatment, particularly in older adults. Understanding the implications of deprescribing in diabetes care is crucial for improving patient outcomes and minimizing risks associated with polypharmacy.
Data Highlights
| Measure | Change |
|---|---|
| Body Mass Index | Decreased by 2 kg/m² |
| Mean Glucose | Decreased by 25% |
| Hemoglobin A1c | Decreased by 13% |
| Deprescribing Events | 41 events (6% of cohort) |
Key Findings
- Deprescribing occurred in 6% of the studied cohort, with 41 confirmed events.
- Mean body mass index decreased by approximately 2 kg/m² over a mean follow-up of 47 months.
- Mean glucose levels decreased by 25% and hemoglobin A1c by 13% among patients who underwent deprescribing.
- Common deprescribing actions included metformin dose reductions (34%) and discontinuations (20%).
- 51% of deprescribed cases documented lifestyle changes, primarily dietary and physical activity modifications.
Clinical Implications
Highlight the importance of monitoring and structured frameworks for deprescribing.
Conclusion
This study highlights the potential benefits of deprescribing glucose-lowering medications in type 2 diabetes management, suggesting that it can lead to improved metabolic outcomes without serious adverse events. Further research is needed to establish causality and optimize deprescribing protocols.
Related Resources & Content
- The Journal of Clinical Endocrinology & Metabolism, 2023 -- Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes
- The Journal of Clinical Endocrinology & Metabolism, 2023 -- The Interplay Between Mental Health and Diabetes Care Management
- The Journal of Clinical Endocrinology & Metabolism, 2023 -- Exploring Four Evidence-Supported Dietary Approaches for Managing Type 2 Diabetes
- Summary of Revisions: Standards of Care in Diabetes—2026 - PMC
- conexiant — Diabetes Self-Care Declines During Breast Cancer Treatment
- Diabetes Self-Care Declines During Breast Cancer Treatment
- 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT)
- Association between hypoglycaemic drug de-intensification, mortality and hospital admission in older adults with type 2 diabetes
- Summary of Revisions: Standards of Care in Diabetes—2026 - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
